Genetic Technologies Ltd. ADR (GENE) News
Filter GENE News Items
GENE News Results
Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
GENE News Highlights
- GENE's 30 day story count now stands at 2.
- Over the past 16 days, the trend for GENE's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- GOLD and PAY are the most mentioned tickers in articles about GENE.
Latest GENE News From Around the Web
Below are the latest news stories about GENETIC TECHNOLOGIES LTD that investors may wish to consider to help them evaluate GENE as an investment opportunity.
Here's Why Shareholders May Want To Be Cautious With Increasing Genetic Technologies Limited's (ASX:GTG) CEO Pay PacketKey Insights Genetic Technologies to hold its Annual General Meeting on 21st of November Total pay for CEO Simon... |
Gene Business Update: Private Hospital Partnership; Expanded Multi-Test for Australian Market and Commercial Partner for Cancer Clinical TrialMELBOURNE, Australia, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, ”Company”, “GTG”), a global leader in guideline-driven genomics-based testing in health, wellness and serious diseases, is pleased to provide an update on the company activities for the quarter ending 30 September 2023. Highlights: Partnership signed with the Gold Coast Private Hospital (a member of Healthscope), to establish a Precision Medicine Clinic at the hospital.GeneType Multi-Test |
GeneType Predicting Risk of Pancreatic Cancer: Major Breakthrough in Early Detection and TreatmentMELBOURNE, Australia, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the publication of a peer-reviewed research paper validating geneType’s Pancreatic Cancer risk assessment test. Highlights: Pancreatic cancer has a very high mortality rate, approximately 76%1 of those diagnosed will die within 1 year. The five-year survival rate is |
Knightscope, Soligenix, and Genetic Technologies Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TVORLANDO, FL / ACCESSWIRE / October 6, 2023 / RedChip Companies will air interviews with Knightscope, Inc. (NASDAQ:KSCP), Soligenix, Inc. (Nasdaq:SNGX), and Genetic Technologies Limited (ASX:GTG)(NASDAQ:GENE) on The RedChip Small Stocks Big Money Show®, ... |
Genetic Technologies building pathway to profitabilityGenetic Technologies Ltd (ASX:GTG; NASDAQ:GENE) CEO Simon Morriss tells Proactive the focus over the next 18 years is putting the pathway in place to see the business on track to profitability. GTG... |
GTG Signs Precision Medicine Pilot with Australia’s Largest Private Hospital NetworkGeneType and Gold Coast Hospital Simon Morriss - Genetic Technologies Ltd CEO and Michelle Ferrari Cestari - Gold Coast Hospital Research Manager GTG CEO, Simon Morriss, is pleased to announce collaboration with Gold Coast Hospital Simon Morriss, Genetic Technologies CEO's Statement MELBOURNE, Australia, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) – a global leader in genomics-based tests in health, wellness and serious disease is pl |
Aridis Pharmaceuticals, Inc., Genetic Technologies Limited, and American Resources Corporation Interviews to Air on the RedChip Money Report(R) on Bloomberg TVRedChip Companies will air interviews with Aridis Pharmaceuticals, Inc. (OTC:ARDS), Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE), and American Resources Corporation (Nasdaq:AREC) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 16, at 7 p.m. Eastern Time (ET). |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayIt's time for another dive into the biggest pre-market stock movers as we check out all the shares worth watching on Wednesday! |
Breakthrough: GeneType for Pancreatic Cancer, Melanoma, and Atrial Fibrillation Cleared for Australian ReleaseGenetic Technologies Limited (ASX: GTG; NASDAQ: GENE) Expands Reach of Revolutionary geneType Multi-Risk Test in Australia: A major advancement towards preventative Healthcare MELBOURNE, Australia, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (GTG), a pioneering global leader in genomics-based tests focused on health, wellness, and the battle against serious diseases, proudly announces a groundbreaking development. The expanded geneType Multi-Risk Test is now readily accessibl |
Genetic Technologies Limited and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Money Report® on Bloomberg TVMELBOURNE, Australia, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline driven genomics-based tests in health, wellness and serious disease is pleased to advise that RedChip Companies will air interviews with Genetic Technologies Limited (Nasdaq: GENE) and 60 Degrees Pharmaceuticals (60P) (NASDAQ: SXTP) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 2, at 7 p.m. Eas |